A
Ardelyx, Inc. (ARDX)
NGM – Real vaqt narxi. Valyuta: USD
6.20
-0.41 (-6.20%)
Bozor ochiq: May 13, 2026, 9:42 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
6.20
-0.41 (-6.20%)
Bozor ochiq: May 13, 2026, 9:42 AM EDT
Ardelyx, Inc. Qo'shma Shtatlar va xalqaro miqyosda tibbiy ehtiyojlarni qondirmaydigan kasalliklarni davolash uchun dori-darmonlarni kashf etadi, ishlab chiqadi va tijoratlashtiradi. Kompaniya IBSRELA, ich qotishi bilan kechuvchi tirqishli ichak sindromi bilan og'rigan bemorlarni davolash uchun kam so'riladigan kichik molekulali terapiyani; va XPHOZAH, dializdagi surunkali buyrak kasalligi bo'lgan kattalarda zardobdagi fosforni kamaytirish uchun fosfatni singdiruvchi ingibitorni taklif etadi. Ardelyx, Inc. ilgari Nteryx, Inc. nomi bilan tanilgan va 2008 yil iyun oyida Ardelyx, Inc. nomini olgan. Kompaniya 2007 yilda tashkil etilgan va shtab-kvartirasi Uoltem, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. John Bishop Ph.D. | Chief Technical & Quality Officer |
| Dr. Laura A. Williams M.D., M.P.H. | Chief Patient Officer & Interim Chief Medical Officer |
| Mr. Eric Duane Foster | Chief Commercial Officer |
| Mr. James P. Brady | Chief Human Resources Officer |
| Mr. Joseph Reilly | Senior VP of Finance & Principal Accounting Officer |
| Mr. Michael G. Raab | President, CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | 8-K | ardx-20260430.htm |
| 2026-04-30 | 10-Q | ardx-20260331.htm |
| 2026-04-29 | DEF 14A | ny20065368x1_def14a.htm |
| 2026-04-29 | ARS | ny20065368x2_ars.pdf |
| 2026-02-19 | 8-K | ardx-20260219.htm |
| 2026-02-19 | 10-K | ardx-20251231.htm |
| 2026-01-08 | 8-K | ardx-20260108.htm |
| 2025-12-17 | 8-K | ardx-20251217.htm |
| 2025-11-03 | S-8 | d45140ds8.htm |
| 2025-11-03 | S-3ASR | d34492ds3asr.htm |
| Mr. Mike Kelliher | Chief Business Officer |
| Ms. Caitlin Lowie | Vice President of Corporate Communications & Investor Relations |
| Ms. Felecia W. Ettenberg | Chief Legal Officer |
| Ms. Sue Hohenleitner | Chief Financial Officer |